KPI-121 1% Versus Prednisolone for the Treatment of Inflammation Following Cataract Surgery in Children
Overview
This study is designed to assess how KPI-121 1% compares to prednisolone acetate in reducing inflammation after cataract surgery in young children. Approximately half the participants will receive KPI-121 1% eye drops and the other half will receive prednisolone acetate.
Full Title of Study: “Safety and Efficacy of KPI-121 1% Ophthalmic Suspension Versus Prednisolone Acetate Ophthalmic Suspension 1% for the Treatment of Inflammation Following Cataract Surgery in Children 0 to 3 Years of Age”
Study Type
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Primary Purpose: Treatment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Study Primary Completion Date: September 28, 2018
Interventions
- Drug: KPI-121 1%
- eye drops
- Drug: Prednisolone acetate
- eye drops
Arms, Groups and Cohorts
- Experimental: KPI-121 1% BID (twice daily)
- Active Comparator: Prednisolone acetate QID (four times daily)
Clinical Trial Outcome Measures
Primary Measures
- Anterior Chamber Cell Grade
- Time Frame: Day 15
- Anterior chamber cell grading is a way of quantifying the amount of inflammation in inflammatory eye processes. Higher values indicate greater inflammation. The anterior chamber cell grading uses whole numbers from 0 (no cells) to 4 (> 30 cells) as follows: Anterior chamber cell grade 0 = no cells seen Anterior chamber cell grade 1 = 1 – 5 cells Anterior chamber cell grade 2 = 6 – 15 cells Anterior chamber cell grade 4 = greater than 30 cells
Secondary Measures
- Modified Global Overall Assessment of Postoperative Inflammation
- Time Frame: Day 15
- The Modified Global Overall Assessment is a way of quantifying the amount of post operative healing that has occurred. Lower values indicate greater healing.The Modified Global Assessment grading uses whole numbers from 0 (clear) to 2 (not improving or worsening) as follows: 0 = clear = improving satisfactorily = not improving or worsening
Participating in This Clinical Trial
Inclusion Criteria
- Be a candidate for routine, uncomplicated cataract surgery Exclusion Criteria:
- Have a post-traumatic cataract. – Have suspected permanent low vision or blindness in the fellow non-study eye. – Have active uveitis in either eye. – Have an ocular neoplasm in either eye. – Have the presence of viral, bacterial, or fungal disease in either eye. – Have glaucoma, ocular hypertension, steroid-induced IOP (intraocular pressure) rise or elevated IOP
Gender Eligibility: All
Minimum Age: N/A
Maximum Age: 3 Years
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Kala Pharmaceuticals, Inc.
- Provider of Information About this Clinical Study
- Sponsor
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.